Harmony Biosciences Holdings (HRMY) Non-Current Debt (2019 - 2026)

Harmony Biosciences Holdings' Non-Current Debt history runs 8 years deep, the most recent figure standing at $138.8 million for Q1 2026.

• In Q1 2026, Non-Current Debt fell 12.24% year-over-year to $138.8 million; the TTM figure through Mar 2026 stood at $138.8 million (down 12.24% YoY), while the FY2025 annual figure was $143.7 million, down 11.87% from the prior year.
• Non-Current Debt came in at $138.8 million for Q1 2026 at Harmony Biosciences Holdings, down from $143.7 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $189.9 million in Q1 2022 to a low of $138.8 million in Q1 2026.
• A 5-year average of $170.9 million and a median of $175.0 million in 2024 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt decreased 0.18% in 2022 and fell 12.24% in 2026, its largest moves.
• Harmony Biosciences Holdings' Non-Current Debt stood at $189.6 million in 2022, then slipped by 5.84% to $178.6 million in 2023, then dropped by 8.71% to $163.0 million in 2024, then slipped by 11.87% to $143.7 million in 2025, then dropped by 3.38% to $138.8 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $138.8 million, $143.7 million, and $148.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison